Is REGENXBIO Inc. (RGNX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 18.7% / 30% | 53.6% / 30% | 4.9% / 30% | 0.21% / 5% | ✗ NOT HALAL |
| DJIM | 18.7% / 33% | 53.6% / 33% | 4.9% / 33% | 0.21% / 5% | ✗ NOT HALAL |
| MSCI | 17.6% / 33% | 50.4% / 33% | 4.6% / 33% | 0.21% / 5% | ✗ NOT HALAL |
| S&P | 18.7% / 33% | 53.6% / 33% | 4.9% / 33% | 0.21% / 5% | ✗ NOT HALAL |
| FTSE | 17.6% / 33% | 50.4% / 33% | 4.6% / 50% | 0.21% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -45.9% | |
| Operating Margin | -190.0% | |
| Net Margin | -113.8% | |
| Return on Equity (ROE) | -107.0% | |
| Return on Assets (ROA) | -21.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$124M |
| Free Cash Flow | -$126M |
| Total Debt | $74M |
| Debt-to-Equity | 253.6 |
| Current Ratio | 2.4 |
| Total Assets | $453M |
Price & Trading
| Last Close | $8.26 |
| 50-Day MA | $9.87 |
| 200-Day MA | $10.52 |
| Avg Volume | 1.0M |
| Beta | 1.1 |
|
52-Week Range
$5.04
| |
About REGENXBIO Inc. (RGNX)
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is REGENXBIO Inc. (RGNX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), REGENXBIO Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is REGENXBIO Inc.'s debt ratio?
REGENXBIO Inc.'s debt ratio is 18.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 17.6%.
What are REGENXBIO Inc.'s key financial metrics?
REGENXBIO Inc. has a market capitalization of $401M, and revenue of $170M. The company maintains a gross margin of -45.9% and a net margin of -113.8%. Return on equity stands at -107.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.